The specimen validity testing market size has grown strongly in recent years. It will grow from $3.37 billion in 2023 to $3.68 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing drug adoption, increased drug screening, stringent regulations, increased alcohol use, and integration of point-of-care testing.
The specimen validity testing market size is expected to see strong growth in the next few years. It will grow to $5.27 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The projected growth in the forecast period can be attributed to several factors, including the increasing demand for workplace drug testing, the growing adoption of oral fluid testing methods, a rise in research and development activities, the expanding utilization of Specimen Validity Testing (SVT), and the broadening applications in pain management. Key trends expected in the forecast period encompass technological advancements, the integration of artificial intelligence for result interpretation, product innovations, increasing partnerships within the industry, and the development of portable testing devices for on-the-go monitoring.
The increasing prevalence of drug abuse is anticipated to drive the growth of the specimen validity testing (SVT) market in the future. Drug abuse involves the habitual, excessive, or inappropriate use of legal or illegal substances for non-medical purposes and is on the rise due to various interconnected factors, including opioid addiction, escalating mental health issues, limited access to treatment and support resources, and cultural influences. SVT methods are designed to detect the presence of impurities and compounds by assessing various parameters such as pH, specific gravity, creatinine content, and temperature. For example, data from the Office for Health Improvement and Disparities in October 2023 revealed an increase in adult contacts with drug and alcohol programs in the UK, totaling 0.29 million interactions from April 2021 to March 2022, up from 0.28 million the previous year. Additionally, according to the Centers for Disease Control and Prevention in May 2022, opioid overdose deaths in the USA surged by 15%, reaching 80,816 in 2021 from 70,029 in 2020. Hence, the growing incidence of drug abuse is expected to propel the growth of the specimen validity testing market.
Key players in the specimen validity testing market are focused on developing innovative products such as high-resolution urine drug testing profiles to maintain their market position. A high-resolution urine drug testing profile employs advanced analytical techniques for sophisticated testing. For instance, in July 2022, Mayo Clinic Laboratories introduced a data-driven urine drug testing (UDT) profile aimed at providing physicians with comprehensive information to manage patients addicted to common substances such as prescription opioids, alcohol, marijuana, and nicotine. This addiction medicine monitoring profile (Mayo ID ADMPU) complies with the American Society of Addiction Medicine's guidelines and offers enhanced sensitivity and specificity to detect parent drugs and metabolites from various drug classes, including opioids, benzodiazepines, stimulants, and PCP. Utilizing high-resolution, accurate mass spectrometry and targeted immunoassay testing, the profile delivers clinically relevant information for healthcare providers.
In October 2021, Mesa Laboratories Inc. acquired Agena Bioscience for $300 million, aiming to expand its presence in the clinical genomics sector by integrating Agena Bioscience's innovative molecular diagnostics tools and genetic analysis solutions into its portfolio. This strategic move enhances Mesa's capabilities in providing critical quality control solutions for the pharmaceutical, healthcare, and medical device industries. Agena Bioscience, known for its cutting-edge technologies and groundbreaking molecular genomics research, including sample validity testing, aligns well with Mesa Laboratories' objectives in advancing diagnostic solutions.
Major companies operating in the specimen validity testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Medline Industries Inc., Becton, Dickinson and Company, Laboratory Corporation, Quest Diagnostics Incorporated, Alere Inc., Clinical Reference Laboratory Inc., Precision Diagnostics, ACM Global Laboratories, Millennium Health, Omega Laboratories Inc., Dominion Diagnostics, CannAmm, Sciteck Inc., Starplex Scientific Inc., Vision Diagnostics Inc., Premier Biotech Inc., Alfa Scientific Designs, Express Diagnostics, American Bio Medica Corporation, Titan Biotech Ltd., SureHire, Miraclean Technology Co. Ltd.
North America was the largest region in the specimen validity testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specimen validity testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the specimen validity testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Specimen Validity Testing (SVT) is a crucial process utilized to evaluate the integrity and authenticity of biological specimens, including urine, blood, saliva, or hair samples, collected for drug testing or clinical analysis. SVT scrutinizes diverse parameters such as pH, creatinine levels, specific gravity, and the presence of common masking agents such as oxidizing adulterants, nitrites, glutaraldehyde, and pyridinium chlorochromate.
Within the specimen validity testing market, products and services are the main offerings. Products encompass assay kits, reagents, calibrators, and disposables employed in the testing procedure to identify any adulteration, dilution, or substitution in urine samples. Various testing types include laboratory testing and rapid or point-of-care testing, catering to a range of end-users such as drug rehabilitation centers, drug screening laboratories, pain management centers, criminal justice and law enforcement agencies, among others.
The specimen validity testing market research report is one of a series of new reports that provides specimen validity testing market statistics, including the specimen validity testing industry global market size, regional shares, competitors with a specimen validity testing market share, detailed specimen validity testing market segments, market trends, and opportunities, and any further data you may need to thrive in the specimen validity testing industry. This specimen validity testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The specimen validity testing market includes revenues earned by entities by creatinine testing, pH testing, adulterant testing, and specific gravity measurement and related specimen collection containers, urine test strips, adulterant detection kits, and temperature strips. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The specimen validity testing market size is expected to see strong growth in the next few years. It will grow to $5.27 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The projected growth in the forecast period can be attributed to several factors, including the increasing demand for workplace drug testing, the growing adoption of oral fluid testing methods, a rise in research and development activities, the expanding utilization of Specimen Validity Testing (SVT), and the broadening applications in pain management. Key trends expected in the forecast period encompass technological advancements, the integration of artificial intelligence for result interpretation, product innovations, increasing partnerships within the industry, and the development of portable testing devices for on-the-go monitoring.
The increasing prevalence of drug abuse is anticipated to drive the growth of the specimen validity testing (SVT) market in the future. Drug abuse involves the habitual, excessive, or inappropriate use of legal or illegal substances for non-medical purposes and is on the rise due to various interconnected factors, including opioid addiction, escalating mental health issues, limited access to treatment and support resources, and cultural influences. SVT methods are designed to detect the presence of impurities and compounds by assessing various parameters such as pH, specific gravity, creatinine content, and temperature. For example, data from the Office for Health Improvement and Disparities in October 2023 revealed an increase in adult contacts with drug and alcohol programs in the UK, totaling 0.29 million interactions from April 2021 to March 2022, up from 0.28 million the previous year. Additionally, according to the Centers for Disease Control and Prevention in May 2022, opioid overdose deaths in the USA surged by 15%, reaching 80,816 in 2021 from 70,029 in 2020. Hence, the growing incidence of drug abuse is expected to propel the growth of the specimen validity testing market.
Key players in the specimen validity testing market are focused on developing innovative products such as high-resolution urine drug testing profiles to maintain their market position. A high-resolution urine drug testing profile employs advanced analytical techniques for sophisticated testing. For instance, in July 2022, Mayo Clinic Laboratories introduced a data-driven urine drug testing (UDT) profile aimed at providing physicians with comprehensive information to manage patients addicted to common substances such as prescription opioids, alcohol, marijuana, and nicotine. This addiction medicine monitoring profile (Mayo ID ADMPU) complies with the American Society of Addiction Medicine's guidelines and offers enhanced sensitivity and specificity to detect parent drugs and metabolites from various drug classes, including opioids, benzodiazepines, stimulants, and PCP. Utilizing high-resolution, accurate mass spectrometry and targeted immunoassay testing, the profile delivers clinically relevant information for healthcare providers.
In October 2021, Mesa Laboratories Inc. acquired Agena Bioscience for $300 million, aiming to expand its presence in the clinical genomics sector by integrating Agena Bioscience's innovative molecular diagnostics tools and genetic analysis solutions into its portfolio. This strategic move enhances Mesa's capabilities in providing critical quality control solutions for the pharmaceutical, healthcare, and medical device industries. Agena Bioscience, known for its cutting-edge technologies and groundbreaking molecular genomics research, including sample validity testing, aligns well with Mesa Laboratories' objectives in advancing diagnostic solutions.
Major companies operating in the specimen validity testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Medline Industries Inc., Becton, Dickinson and Company, Laboratory Corporation, Quest Diagnostics Incorporated, Alere Inc., Clinical Reference Laboratory Inc., Precision Diagnostics, ACM Global Laboratories, Millennium Health, Omega Laboratories Inc., Dominion Diagnostics, CannAmm, Sciteck Inc., Starplex Scientific Inc., Vision Diagnostics Inc., Premier Biotech Inc., Alfa Scientific Designs, Express Diagnostics, American Bio Medica Corporation, Titan Biotech Ltd., SureHire, Miraclean Technology Co. Ltd.
North America was the largest region in the specimen validity testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specimen validity testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the specimen validity testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Specimen Validity Testing (SVT) is a crucial process utilized to evaluate the integrity and authenticity of biological specimens, including urine, blood, saliva, or hair samples, collected for drug testing or clinical analysis. SVT scrutinizes diverse parameters such as pH, creatinine levels, specific gravity, and the presence of common masking agents such as oxidizing adulterants, nitrites, glutaraldehyde, and pyridinium chlorochromate.
Within the specimen validity testing market, products and services are the main offerings. Products encompass assay kits, reagents, calibrators, and disposables employed in the testing procedure to identify any adulteration, dilution, or substitution in urine samples. Various testing types include laboratory testing and rapid or point-of-care testing, catering to a range of end-users such as drug rehabilitation centers, drug screening laboratories, pain management centers, criminal justice and law enforcement agencies, among others.
The specimen validity testing market research report is one of a series of new reports that provides specimen validity testing market statistics, including the specimen validity testing industry global market size, regional shares, competitors with a specimen validity testing market share, detailed specimen validity testing market segments, market trends, and opportunities, and any further data you may need to thrive in the specimen validity testing industry. This specimen validity testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The specimen validity testing market includes revenues earned by entities by creatinine testing, pH testing, adulterant testing, and specific gravity measurement and related specimen collection containers, urine test strips, adulterant detection kits, and temperature strips. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Specimen Validity Testing Market Characteristics3. Specimen Validity Testing Market Trends and Strategies32. Global Specimen Validity Testing Market Competitive Benchmarking33. Global Specimen Validity Testing Market Competitive Dashboard34. Key Mergers and Acquisitions in the Specimen Validity Testing Market
4. Specimen Validity Testing Market - Macro Economic Scenario
5. Global Specimen Validity Testing Market Size and Growth
6. Specimen Validity Testing Market Segmentation
7. Specimen Validity Testing Market Regional and Country Analysis
8. Asia-Pacific Specimen Validity Testing Market
9. China Specimen Validity Testing Market
10. India Specimen Validity Testing Market
11. Japan Specimen Validity Testing Market
12. Australia Specimen Validity Testing Market
13. Indonesia Specimen Validity Testing Market
14. South Korea Specimen Validity Testing Market
15. Western Europe Specimen Validity Testing Market
16. UK Specimen Validity Testing Market
17. Germany Specimen Validity Testing Market
18. France Specimen Validity Testing Market
19. Italy Specimen Validity Testing Market
20. Spain Specimen Validity Testing Market
21. Eastern Europe Specimen Validity Testing Market
22. Russia Specimen Validity Testing Market
23. North America Specimen Validity Testing Market
24. USA Specimen Validity Testing Market
25. Canada Specimen Validity Testing Market
26. South America Specimen Validity Testing Market
27. Brazil Specimen Validity Testing Market
28. Middle East Specimen Validity Testing Market
29. Africa Specimen Validity Testing Market
30. Specimen Validity Testing Market Competitive Landscape and Company Profiles
31. Specimen Validity Testing Market Other Major and Innovative Companies
35. Specimen Validity Testing Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Specimen Validity Testing Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on specimen validity testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for specimen validity testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The specimen validity testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product And Service: Products; Service2) By Testing Type: Laboratory Testing; Rapid Or Point-Of-Care Testing
3) By End-User: Drug Rehabilitation Centers; Drug Screening Laboratories; Pain Management Centers; Criminal Justice And Law Enforcement Agencies; Other End-Users
Key Companies Mentioned: Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Siemens Healthineers ; Medline Industries Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers
- Medline Industries Inc.
- Becton, Dickinson and Company
- Laboratory Corporation
- Quest Diagnostics Incorporated
- Alere Inc.
- Clinical Reference Laboratory Inc.
- Precision Diagnostics
- ACM Global Laboratories
- Millennium Health
- Omega Laboratories Inc.
- Dominion Diagnostics
- CannAmm
- Sciteck Inc.
- Starplex Scientific Inc.
- Vision Diagnostics Inc.
- Premier Biotech Inc.
- Alfa Scientific Designs
- Express Diagnostics
- American Bio Medica Corporation
- Titan Biotech Ltd.
- SureHire
- Miraclean Technology Co. Ltd
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | July 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 3.68 Billion |
Forecasted Market Value ( USD | $ 5.27 Billion |
Compound Annual Growth Rate | 9.4% |
Regions Covered | Global |